Celldex Therapeutics Inc (CLDX) is a biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and other diseases. As part of their investment analysis, investors often rely on technical analysis to evaluate the current and future price movements of a stock. In this regard, several technical indicators can be used to assess the performance of CLDX stock.

One such indicator is the relative strength index (RSI), which measures the speed and change of price movements. The RSI for CLDX stock can give investors an idea of whether the stock is overbought or oversold. Another indicator is the average directional index (ADX), which measures the strength of a trend. By analyzing the ADX for CLDX stock, investors can determine the likelihood of a continuation or reversal of the current trend.

Celldex Therapeutics  (CLDX) Technical Analysis

Learn about the technical analysis indicators for Celldex Therapeutics Inc (CLDX) stock including RSI, ADX, and MACD. Find out more about the stock's Rate of Change (ROC), STOCHRSI, and WILLR. Discover the technical analysis rating for CLDX.

Celldex Therapeutics Inc (CLDX) Technical Analysis | RSI, ADX, MACD

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphMACD	-28.86	Neutral	80.5%
auto_graphCCI	-116.92	Buy	26.2%
auto_graphADX	45.80	Neutral	87.6%
auto_graphATR	20.81	Buy	-
auto_graphWILLR	-89.17	Buy	59.2%
auto_graphROC	-40.36	Neutral	42.1%
auto_graphSTOCHRSI	52.10	Neutral	-4.8%
auto_graphRSI	31.07	Neutral	-

Buy	3	-62.50%
Hold	5	-37.50%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Celldex Therapeutics (CLDX) Technical Analysis

Keep an eye on Celldex Therapeutics

Frequently Asked Questions

What are the technical signals for Celldex Therapeutics (CLDX) stock based on the last 30 days?

Take Your Investments to a Whole New Level